Do you have any advice when utilizing palliative radiation therapy in patients currently being treated with a PARP inhibitor?

This is an excellent question and certainly will become more of an issue with the recent FDA approval of olaparib for HR-defective (HRD) metastatic ovarian cancer. In addition, many other HRD metastatic cancers are being treated with this drug under compassionate use. Furthermore, the recent Phase I...